Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age65-85
SponsorUniversity of Colorado, Denver
About this trial
This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.
Eligibility criteria
Qualifiers
Aged 65-85 years & be male, female, or non-binary
Generally healthy
Have an identified support person
Capacity to Consent
Disqualifiers
Unstable medical condition
Risk for hypertensive crisis (screening blood pressure >140/90 mmHg)
Significant central nervous system (CNS) pathology
Primary psychotic or affective psychotic disorders
Trial design
Treatments tested in this trial
- Psilocybin (Usona Institute)
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
6California
University of California San Francisco (UCSF) Department of Neurology94158, San Francisco United States
Colorado
University of Colorado Anschutz Medical Campus80045, Aurora United States
Georgia
Emory University Brain Health Center30329, Atlanta United States
Massachusetts
Dana-Farber Cancer Institute02215, Boston United States
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Institute on Aging (NIA)
Collaborator
University of California, San Francisco
Collaborator
Emory University
Collaborator
Dana-Farber Cancer Institute
Collaborator
NYU Langone Health
Collaborator
University of Nebraska
Collaborator
Source ClinicalTrials.gov